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The aim of the present research was to develop a bilayer tablet of venlafaxine
hydrochloride for bimodal drug release. In the present investigation authors have tried to
explore fenugreek mucilage (FNM) for bioadhesive sustained release layer. The attempt
has been made to combine FNM with well studied bioadhesive polymers like hydroxy
propyl methyl cellulose (HPMC), Carbopol, and Xanthan Gum. The formulations were
evaluated for swelling Index, ex vivo bioadhesion, water uptake studies, in vitro drug
release and dissolution kinetics was studied. Substantial bioadhesion force (2.4 ± 0.023
g) and tablet adhesion retention time (24 ± 2 h) was observed with FNM and HPMC
combination at 80:20 ratio. The dissolution kinetics followed the Higuchi model (R2 =
0.9913) via a non-Fickian diffusion controlled release mechanism after the initial burst.
The 32 full factorial design was employed in the present study. The type of polymers
used in combination with FNM (X1) and percent polymer replaced with FNM (X2) were
taken as independent formulations variables. The selected responses, bioadhesion force
(0.11–0.25 ± 0.023 g), amount of drug released in 10 h, Y10 (78.20–95.78 ± 1.24%)
and bioadhesive strength, (19–24 ± 2 h) presented good correlation with the selected
independent variables. Statistical analysis (ANOVA) of the optimized bilayer formulations
showed no significant difference in the cumulative amount of drug release after 15 min,
but significant difference (p < 0.05) in the amount of drug released after 1 hr till 12
h from optimized formulations was observed. The natural mucilage like FNM could
be successfully incorporated into tablet with only 20% replacement with HPMC and
it showed good bioadhesiveness and sustained drug release.
Keywords: natural polysaccharide, bilayer tablet, immediate release layer, bioadhesive layer, bimodal drug
release, factorial design
Introduction
The new drug delivery system with better eﬃcacy and safety with reduced dosing frequency and
improved patient compliance is the current area of research by formulation development scientists.
Tablet being most preferred dosage form for its ease of manufacturing and patient convenience
is always a ﬁrst choice of dosage form. The single layer tablets leads to frequent dosing and
unpredicted drug plasma level for drugs with shorter half lives (Banker and Anderson, 1986;
Ansel et al., 2011). Number of diseases like schizophrenia require immediate release of drug for
instant eﬀect to manage the panic attack at its presentation and then drug concentration has to be
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maintained for prolong eﬀect of the drug. On the basis of
requirement for such a disease conditions, the multilayered
tablet concept has been utilized (Preeti, 2011). Such a tablet
has a fast releasing layer and may contain bi- or triple layers
to sustain the drug release. Bilayer tablets present a better
choice where one layer provide immediate dose which is
then maintains the plasma drug level by its controlled release
layer of the tablet. Venlafaxine hydrochloride multilayered
tablet has been developed by several scientists and reported
earlier which is frequently prescribed for management of
panic depression attacks. (Gohel and Bariya, 2009; Sharif
et al., 2011; Niwa et al., 2013) Venlafaxine Hcl (VFX) is a
new generation anti-depressant serotonin/noradrenalin reuptake
inhibitor drug showing eﬀective anti-depressant properties. It has
a short biological half-life of 5 h. So, frequent administration
is necessary to maintain its therapeutic concentration. This
necessitates multiple daily dosing of VFX for maintenance of its
plasma concentration within the therapeutic index. Venlafaxine
Hcl (VFX) has site speciﬁc absorption for upper GI tract.
Hence, all these properties make VFX an ideal candidate
for sustained release and bioadhesive drug delivery system
(Muth et al., 1991; Holiday and Benﬁeld, 1995; Budavari,
1996; Parﬁtt, 1999; Makhijal and Vavia, 2002; Prasad et al.,
2010).
Reports have been made for use of sodium starch glycolate
(SSG), Cross carmellose, cross povidone, and Hydroxy propyl
methyl cellulose (HPMC), chitosan, Xanthan Gum in the
formulation of bilayer tablets as superdisintegrants and sustained
release polymer, respectively, in the formulation of bilayer tablets
(Kawtikwar et al., 2009; Reddy et al., 2010; Logidhasan et al.,
2013)
In recent years natural polymers have been widely used
because of their eﬀectiveness and availability over synthetic
polymers. Natural polysaccharides and dried mucilage have been
reported as an emulsifying, suspending agent, binding agent,
disintegrating agent, and as a sustained-release matrix. They
have been utilized in variety of formulations like mucoadhesive,
gastro retentive, colon speciﬁc drug delivery system etc., (Baveja
et al., 1988; Ahuja et al., 1997; Rishabha et al., 2010; Pooja
Abhang et al., 2012; Divani et al., 2013). Flax is an annual
plant of the linaceae family is an annual herb of leguminosae
family. This plant contains natural oligosaccharides (Fedeniuk
and Biliaderis, 1994). Flax seeds produce high viscosity mucilage
at low concentration levels. it has good water-holding capacities,
owing to its marked swelling capacity and high viscosity in
aqueous solution. The same reports have presented results for
its application as a binder as well as bioadhesive matrix forming
agent (Nerkar and Gattani, 2011, 2013; Pooja Abhang et al.,
2012).
In the present study, a bilayer tablet for bimodal drug release
in which one layer of immediate release and second layer of
sustained release of VFX was designed. The sustained release
layer was formulated using FNM in combination with HPMC
K 100 M, Carbopol 934P, and Xanthan Gum. The immediate
layer was formulated using superdisintegrants such as SSG,
Cross-Carmellose sodium, and Cross-Povidone. In the present
study a systematic approach has been adopted to study the
eﬀect of FNM in combination with a lowest possible level
of well known bioadhesive hydrophilic polymers like, HPMC,
Xanthan Gum, and Carbopol. The present formulation will
meet the need of an antidepressant with shorter half life to
immediately release the drug to control the panic attack and
then maintain the plasma concentration for managing the further
symptoms.
Statistical optimization techniques are frequently employed
for the development of pharmaceutical formulations
(Vinayagamkannan et al., 2003). A 32 full factorial design is
the simple experimental design with two variables studied at
three levels. In the present study, the type of polymers used in
combination with FNM (X1) and percent polymer replaced with
FNM (X2) to achieve required bioadhesion and sustained release
of VFX were taken as independent formulations variables. The
amount of drug released in 10 h (Y10), bioadhesive strength
and bioadhesion time were taken as the dependent response
variables.
Materials
Venlafaxine HCl VFX was received as a gift sample by Shree
Pharmaceutical Ltd., Mehasana, Gujarat, India. Fenugreek seed
was procured from local market of chembur, Mumbai, India.
Hydroxypropylmethyl cellulose K 100 (HPMC) were obtained as
a gift sample from Colorcon Asia Pvt. Ltd., Goa. Carbopol 934P,
Xanthan Gum, SSG, cross carmellose sodium, cross povidone,
Microcrystalline cellulose (MCC), magnesium stearate, and Talc
were procured from S. D Fine Chemicals, Mumbai, India.
Ethanol was obtained fromGoggia and company, Mumbai, India.
Goat stomach mucosa for determining bioadhesive strength was
obtained from a local slaughter house of Mumbai, India. All other
chemicals and reagents used were of analytical grade, and were
used as received.
Methods
Isolation of Fenugreek Mucilage
The fenugreek seeds (Trigonella foenum graceumL.) used in study
was procured from a local market in Mumbai, India. The seeds
were authenticated by Professor Harshad Pandit, Khalsa College,
Mumbai, India.
The isolation of mucilage of fenugreek seeds (FNM) was done
by method described by Pooja Abhang et al. (2012). Brieﬂy,
100 g of crushed fenugreek seeds was soaked in 500 ml of
double distilled water for overnight and boiled at 80◦C using
water bath for 4 h with occasional stirring or till thick mass was
obtained. It was kept aside at room temperature for 4 h with
intermittent stirring and then kept aside for overnight below
20◦C. The hydrated mucilage was separated by using muslin
cloth. The mucilage was then precipitated with 300ml of absolute
alcohol. The precipitated mucilage was ﬁltered using vacuum
ﬁltration. The ﬁltered mucilage was then dehydrated with 200 ml
of acetone. This treatment also removes any oil if present in
hydrated mucilage. After ﬁltration precipitated mass was dried
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in hot air oven at 50◦C for 12 h. The dried mucilage was then
powdered using mortar and pestle and passed through sieve 60.
Dose Calculation According to the Half Life
The total dose of venlafaxine for the loading dose in immediate
layer and maintenance dose in sustained release layer of bilayer
tablet was calculated by following equation using available
pharmacokinetic data (Karna, 2012).
Dt = Dose (1 + 0.693 × t/t1/2)
Where, Dt = Total dose of drug
Dose = dose of immediate release part (37.5 mg)
t = Time (hours) during which the sustained release is desired
(12 h)
t1/2 = Half-life of drug (5)
Dt = 37.5 (1 + 0.693 × 12/5) = 99.87 mg
In the preparation of bilayer tablet, fraction of the drug in
both the phase was adjusted as per USP requirement for initial
drug release of 50–60%. Hence the present formulations contain
total dose of 87.5 mg which includes 37.5 mg as a loading dose
in immediate release layer and 50 mg is a maintenance dose in
sustained release layer.
Preparation and Characterization of Bilayer
Tablets
To formulate bilayer tablets, fast-release, and sustained-release
layers were initially prepared separately to study the dissolution
proﬁle of each layer with an objective of selecting the optimized
combination of excepients for the formulations. The optimized
formulation of each layer was then compressed to bilayer tablet
and further in vitro drug dissolution data were compared with
the marketed product.
Formulation of the Immediate Release Layer
The dose in the formulation for immediate release layer was
37.5 mg. The immediate release tablet was prepared by blending
venlafaxine hydrochloride uniformly with diﬀerent type of super
disintegrants (SSG, cross povidone and cross carmellose sodium)
as per the formulae given in Table 1. The drug-superdisintegrant
blend was then mixed with MCC using twin blender for 10 min.
The ﬁnal mass was lubricated with 0.5%w/w magnesium stearate
TABLE 1 | Formulation design for immediate release tablets.
Ingredient B1 B2 B3 B4 B5 B6
Venlafaxine(mg) 37.5 37.5 37.5 37.5 37.5 37.5
sodium starch
glycolate (SSG) (%)
5 10 – – – –
Crosspovidone (%) – – 5 10 – –
Crosscarmellose (%) – – – – 5 10
Microcrystalline
cellulose (MCC) (mg)
142.5 142.5 142.5 142.5 142.5 142.5
Total (mg) 200 200 200 200 200 200
and 0.5%w/w talc and compressed using Rotary Mini tablet press
(Karnavati Pvt. Ltd., India) using 11 mm ﬂat beveled punches.
The tablets were evaluated for weight variation, thickness,
friability, hardness, and disintegration time.
Formulation of the Sustained Release Layer
The sustained release layer of the tablet was prepared by
wet granulation technique by mixing VFX uniformly with
dried fenugreek mucilage (FNM) powder along with diﬀerent
proportion of HPMC K100 M, carbopol 934P, and Xanthan
Gum as given in Table 2. Polyvinyl pyrolidone K 30 (3% w/v
in IPA) was used as a binder. The wet mass was passed through
30# to obtain granules. The granules were dried at 60◦ in a
tray drier. The granules of 30/60# size were lubricated with 1%
w/w magnesium stearate. The sustained release granules were
compressed using Rotary Mini tablet press (Karnavati Pvt. Ltd.,
India) equipped with 11 mm ﬂat beveled punches. A constant
tablet weight of 400 mg was maintained.
Optimization of the Sustained Release Layer
Using 32 Factorial Design
A 32 full factorial design was applied was employed to
systematically design and develop sustained release bioadhesive
layer for bilayer VFX tablet. The type of polymers used in
combination with FNM (X1) and percent polymer replaced with
FNM (X2) to achieve required bioadhesion and sustained release
of VFX were taken as independent formulations variables. The
amount of drug released in 10 h (Y10), bioadhesive strength and
bioadhesion time were taken as the dependent response variables.
A statistical model incorporating interactive and polynomial
terms was utilized to evaluate the resultant responses. The
polynomial equation generated by this experimental design using
Design Expert 7.1.6 software, State Ease Inc. is as follows,
Y = b0 + b1X1 + b2X2 + b12X1X2 + b11X12
+ b22X22 (1)
where, Y is a response (dependent variable), b0 is an intercept, b1
to b33 are regression coeﬃcients and X1 and X2 are independent
formulation variables.
A total of nine batches were prepared as per the Table 2. Also,
eﬀorts were made to prepare and compare FNM-polymer blend
sustained release tablet with tablets containing no FNM but only
polymers (Carbopol, Xanthan Gum, HPMC). The purpose was
to compare factorial batches for their drug release, bioadhesion,
TABLE 2 | Factorial design coded value layout of Venlafaxine HCl (VFX)
sustained release layer.
Translation of coded levels in actual units
Coded level −1 0 +1
X1: Type of polymer XNG CBP Hydroxy propyl methyl
cellulose (HPMC)
X2 : % replacement with
Fenugreek Mucilage (FNM)
20 40 60
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TABLE 3 | Factorial batches composition with dependent and independent variable values.
Batch Independent formulations variables Dependent variables
X1: Type of Polymer X2: % FNM replaced Y10 Bioadhesion (g) Retention time (h)
Coded value Actual value Coded value Actual value
Factorial batches
F1 −1 XNG −1 20 78.901 0.20 23
F2 −1 XNG 0 40 84.34 0.17 20
F3 −1 XNG +1 60 87.61 0.20 20
F4 0 CBP −1 20 87.239 0.24 24
F5 0 CBP 0 40 82.62 0.11 19
F6 0 CBP +1 60 81.922 0.19 21
F7 +1 HPMC −1 20 84.139 0.18 21
F8 +1 HPMC 0 40 89.395 0.21 21
F9 +1 HPMC +1 60 95.32 0.23 22
Non-factorial batches for comparison purpose
F10 XNG 100 71.2 0.25 26
F11 CBP 100 97.36 0.24 16
F12 HPMC 100 93.2 0.26 17
and retention time with that of formulations containing tablet
without FNM (Batch F10–F12) as per Table 3.
Characterization of Granules
Prior to compression, granules were subjected to
pharmacotechnical characterization. They were evaluated
for tapped density, Carr’s index and angle of repose. Carr’s
compressibility index was calculated from the bulk and tapped
densities (Ansel et al., 2011) using a digital tap density apparatus
(Electrolab Ltd, India).
Compression of Bilayer Tablet
The bilayer tablet of venlafaxine was prepared using a Rotary
Mini tablet press (Karnavati Pvt. Ltd., India) equipped with
11 mm beveled, ﬂat punches. The die was initially ﬁlled with
the weighed amount sustained release portion and were lightly
compressed. Over this compressed layer, the required quantity of
the fast release layer powder mixture was placed and compressed
to obtain hardness of the tablet 6–7 kg/cm2. It was observed that
table compressed at this force did not show any layer separation.
The total weight of the tablet was kept constant, i.e., 400 mg for
all formulation.
Pharmacotechnical Evaluation of Venlafaxine
Bilayer Tablets
The bilayer tablet of venlafaxine were evaluated for
pharmacotechnical parameters like, hardness, friability, weight
variation, thickness uniformity, and content uniformity as per
the method described in oﬃcial pharmacopeia (United States of
Pharmacopoeia Convention [USP], 1999).
In Vitro Dissolution Studies
Release of VFX was determined using a USP 24 (1999) six stage
dissolution rate test apparatus 1 (Labindia Instruments Pvt. Ltd.,
India) at 50 rpm. The dissolution was studied using 900 mL of
simulated gastric ﬂuid (without enzyme, pH 1.2) for 10 h. The
temperature was maintained at 37 ± 0.2◦C. The sample (5 mL)
was withdrawn at every 1 h time intervals and ﬁltered through
Whatman ﬁlter paper (Auroco Pvt. Ltd., Thailand) and replaced
by an equal volume of dissolutionmedium. Samples were suitably
diluted and analyzed for venlafaxine hydrochloride content at
224 nm (United States of Pharmacopoeia Convention [USP],
1999).
Drug-Release Kinetics
In order to investigate the kinetics of drug release from the
sustained release FNM layer of the bilayer tablets, the data
of in vitro drug release were ﬁtted to diﬀerent models. The
program was developed using PCP Disso software developed
by Poona College of Pharmacy, India for zero order, ﬁrst
order, Higuchi, Hixson–Crowell, Korsmeyer–Peppas, models
with ANOVA treatment for the dissolution data.
Zero-order equation (Wagner, 1969) is followed when the
drug dissolution from FNM matrix layer is without disaggregate
of the polymer and drug is released slowly in controlled manner.
The following equation is adopted:
Q = Q0 + k0t
Where Q represents the amount of drug dissolved in time t, Q0 is
the initial amount of the drug in the solution and k0 is the zero
order release constant expressed in units of concentration/time.
First-order equation (Gibaldi and Feldman, 1967; Wagner,
1969) is followed for the release of the drug from the matric and
can be expressed by the ﬁrst order release kinetics equation:
InQ = InQ0 + k1t
where k1 is the ﬁrst order rate constant and t is the time.
Higuchi equation (Higuchi, 1961) is followed when matrix is
swelling and drug release is aﬀected by change in the surface
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area. Higuchi equation deﬁnes a linear dependence of the active
fraction released per unit of surface (Q) on the square root of time
and can be expressed as
Q = kHt1/2
Where Q is the amount of drug release at time t and kH is the
Higuchi release constant.
Hixson–Crowell equation (Hixson and Crowell, 1931) was
used to calculate the data:
Q1/30 − Q1/3t = kst
Where Q0 is the initial amount of drug in the matrix tablet, Qt is
the amount of drug remaining in the dosage form at time t, and
ks is a constant incorporating the surface/volume ratio.
Bioadhesion Studies
A modiﬁed balance method used for determining the ex vivo
mucoadhesive strength (Shidhaye and Saindane, 2009; Shaikh
et al., 2012). Fresh goat mucosa was obtained and used within
2 h of slaughter. The mucosal membrane separated by removing
underlying fat and loose tissues. The membrane was washed with
distilled water and then with 0.1N HCl at 37◦C. The mucosa
was cut into the pieces and washed. A piece of mucosa was tied
to the Teﬂon piece, which was kept in beaker ﬁlled with HCl
pH 1.2, at 37◦C ± 1◦C. The Teﬂon piece was tightly ﬁtted into
a glass beaker so that it just touched the mucosal surface. The
bioadhesive tablet was stuck to the lower side of a pan. The two
sides of the balance made equal before the study. A weight of 5 g
was kept in the right-hand pan, which lowered the pan along with
the tablet over the mucosa. The balance was kept in this position
for 5min to provide contact time for bioadhesion. The weight was
removed. The water (equivalent to weight) was added slowly drop
by drop with an infusion set to the left-hand pan until the tablet
detached from the mucosal surface. The mucoadhesive strength
of the bioadhesive tablet is calculated by formula
Detachment stress (dyne/cm2) = m.g/A
Where, m = the weight added to the balance in gram,
g = acceleration due to gravity taken as 980 cm/sec2, A = area
of tissue exposed and is equal to πr2 (r-the radius of the circular
hole in the aluminum cap).
Bioadhesion Retention Time
The ex vivo bioadhesion time studies were performed (in
triplicate) after application of tablets on freshly cut goat stomach
mucosa. The mucosa was ﬁxed on a glass slide using adhesive
tape and kept in a slanting position in the beaker. A side of
each tablet was wetted with 50 μl ﬂuid and was attached to the
mucosa by applying a light force with a ﬁngertip for 30 s. The
beaker was ﬁlled with 250ml of simulated gastric ﬂuid and kept at
37◦C; a stirring rate of 100 rpm was applied. Tablet behavior and
mucoadhesive time were monitored until complete detachment
or dissolution occurred.
Stability Study
Gastro retentive tablets of venlafaxine hydrochloride formulated
in the present study were subjected to accelerated stability studies
in aluminum/aluminum pouch pack. The tablets of check point
batch F7 were charged for accelerated stability studies at 40◦C
and 75% RH for a period as prescribed by ICH guidelines for
3 months in a stability chamber. Bioadhesive retention time,
mucoadhesive force, and drug dissolution proﬁle of exposed
sample was carried out after every month (Cartensen, 1995).
Results and Discussion
Venlafaxine hydrochloride an antidepressant drug was
formulated in to bilayer tablet comprising immediate release
layer and sustained release layer to achieve loading dose and
maintenance dose, respectively, and to give large duration
of action. Total of nine batches were prepared for sustained
release layer and six batches for immediate release layer. All the
formulations were subjected to pharmacotechnical evaluation.
The drug content of all formulations of sustained release layer
varied between 98.13 and 102.45% w/w with mean ± SD as
100.29 ± 0.5%. Tablet weights of sustained release layer varied
between 389.1 and 401.8 mg (395.45 ± 2.2 mg mean value),
and thickness between 5.9 and 6.2 mm (6.05 ± 0.1 mm). All
the tablets exhibited friability values ranging between 0.220
FIGURE 1 | In vitro drug release profile for Immediate drug release
layer (B6).
FIGURE 2 | In vitro drug release profile for all batches of sustained
release.
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FIGURE 3 | 3-D Graph for effect of independent variables on Y10.
FIGURE 4 | Contour plot for effect of independent variables on the Total Retention Time.
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and 0.399%w/w (0.30 ± 0.14%), far less than the limit of 1%
w/w. Marginal variation in tablet hardness and friability could
be attributed only to the random causes, but not to the matrix
composition. This absence of any signiﬁcant inter- and intra-
batch variability in tablet hardness, friability and thickness, ruled
out any possibility of any change in compression pressure, and
consequently in drug dissolution. All the immediate release
layers disintegrated in <1 min. All six batches of immediate
layer showed thickness, friability, weight variation, and content
uniformity in acceptable limits. The batch B6 containing 10%w/w
crosscarmellose was selected as an optimized formulations due
to its minimum friability (0.01 ± 0.02%) and disintegration
time 5 s.
Bioadhesion studies showed that with an increase in the
amount of either polymer (Xanthan Gum, Carbopol, or HPMC).
Bioadhesion strength increases due to hydration of polymer
by hydrated mucous layer, resulting in reduced glass transition
temperature and increased uncoiling along with an increased
mobility of polymer chains. This tends to increase the adhesive
surface for maximum contact with mucin and ﬂexibility for
interpenetration with mucin. Although the maximum value
of bioadhesive strength was attained at the highest levels
of all the polymers, yet the eﬀect of selected polymers at
selected levels with FNM was found to be almost similar
without signiﬁcant diﬀerence between the batches F1–F9
and F10–F12. The detachment force depicts the change in
bioadhesive strength of tablets with a change in the polymer
level(s).
Bioadhesive retention time for all tablets was found to be
between 19 and 24 h. FNM has very good bioadhesive and
combination of FNM with other polymer also showed a good
bioadhesive retention time. As the percentage of fenugreek is
decreased, the bioadhesive retention time is also decreased.
Combinations of FNM with HPMC and Carbopol have high
retention time.
The in vitro dissolution studies were carried for immediate
as well as sustained release layers. All six batches of immediate
release layer formulations showed almost similar drug
release patten. The Figure 1 shows drug release pattern for
batch B6.
All factorial as well as non-factorial batches of sustained
release layer were subjected to in vitro dissolution studies.
In the present studies, non-factorial batches containing only
HPMC, Carbopol, and Xantham Gum individually were
prepared to compare and study drug release pattern with
factorial batches containing combination of these polymer with
FNM. The Figure 2 depicts the comparative drug release
proﬁle for all optimization batches along with marketed
product.
All the polynomial equations were found to be statistically
signiﬁcant (P < 0.01), as determined using ANOVA, as per the
provision of Design Expert software. The polynomial equations
comprise the coeﬃcients for intercept, ﬁrst-order main eﬀects,
interaction terms, and the higher order eﬀects. The sign and
magnitude of the main eﬀects signify the relative inﬂuence of each
factor on the response.
The independent variable, Y10, Bioadhesion force, and
bioadhesion Retention Time were compared statistically using
Design Expert software and polynomial equation was derived.
The Figure 3 depicts the eﬀect of polymer and type of polymer
FIGURE 5 | Contour plot for effect of independent variables on the Bioadhesion Force.
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used in combination with FNM at diﬀerent level. From Eqs 2–4,
it can be concluded that, Xanthan Gum has a predominant eﬀect
on drug release, as compared to Carbopol and HPMC. Xanthan
Gumhas a negative eﬀect on the amount of drug releaseWhereas,
Carbopol and FNM combination does not sustain drug release
signiﬁcantly. Figure 3 depicts the response surface plot, showing
the inﬂuence of HPMC, Xanthan Gum, and Carbopol-934P on
Y10. The surface plot shows that Y10 varies as the concentration
of the three polymers changes. From the contour plot (Figures 4
and 5), it can be concluded that all polymers at the selected
levels with FNM signiﬁcantly aﬀect the bioadhesive strength and
retention time. Figure 5 presents the corresponding contour
plot, showing the relationship between various levels of the three
polymers.
From this graph and the derived polynomial equation it can
be concluded that FNM: HPMC at 20:80 ratio could sustain drug
release eﬀectively till 10th hour as compared to carbopol and
xanthan gum.
Y10 = 86.01 − 1.71X1 − 2.39X2 − 3.00X1X2 − 0.56X12
− 2.08 X22 + 1.28X12X2 + 5.02X1X22 − X12X22
(R2 = 0.997,P < 0.05) (2)
Similarly, bioadhesion force and bioadhesion retention time have
also shown signiﬁcant eﬀect based on combination of FNM with
studied polymers. A good bioadhesion retention time for tablet
was observed when higher amount of HPMC or carbopol was
incorporated in the tablet (Figure 4). A satisfactory result and
most optimized result in terms of bioadhesion force and retention
was obtained when FNM was replaced by 20% of its weight with
HPMC (Figure 5).
Bioadhesion Force = + 0.299 − 0.014X1 − 7.19X2
+ 6.13X1X2 + 0.016X12 + 8.19X22
(R2 = 0.877,P = 0.065) (3)
Bioadhesion Retention Time =
+ 29.11 − 1.83X1 − 0.408X2 + 0.055X1X2
− 1.66X12 + 4.58X22 (R2 = 0.784,P = 0.0925) (4)
Dissolution parameters, shows that the value of n varies between
0.3963 and 0.6936, delineating non-Fickian release behavior
(Table 4). The values of n show increasing trend with increase
in HPMC content, However, the release of carbopol and
Xanthan Gum is very slow and n seems to bear a nonlinear
relationship. It shows a rising trend in the values of n as the
content of FNM is increased with signiﬁcant increase at the
highest levels. The values of k followed a declining trend with
increase in the amount of either polymer. Relatively much
higher magnitude of k1 clearly shows that the drug release
was predominantly Fickian diﬀusion, with the contribution of
polymer relaxation as nearly negligible. The overall rate of drug
release tended to decrease with increase in concentration of
Xanthan Gum and carbopol. Similarly, the values of Release
at 10 h increased with increase in the polymer content of
FNM : HPMC. The values of 12 h were found to enhance
FIGURE 6 | comparison of marketed product and optimized batch BF7.
TABLE 4 | Drug release kinetics data for all formulations.
Batch Zero order First order Matrix Peppas Hix.Crow Best fit model
R2 K R2 K R2 K R2 K N R2 K
F1 0.614 9.17 0.905 −0.16 0.978 25.95 0.996 30.75 0.41 0.839 −0.043 Peppas
F2 0.585 9.751 0.935 −0.180 0.976 27.57 0.993 33.93 0.39 0.858 −0.047 Peppas
F3 0.637 10.100 0.964 −0.197 0.982 28.47 0.994 34.52 0.39 0.899 −0.051 Peppas
F4 0.724 9.528 0.981 −0.178 0.991 26.68 0.988 31.60 0.41 0.936 −0.047 matrix
F5 0.877 8.312 0.988 −0.140 0.997 22.89 0.997 21.36 0.54 0.975 −0.038 Peppas
F6 0.8752 8.163 0.984 −0.136 0.997 22.49 0.996 21.65 0.52 0.972 −0.037 Matrix
F7 0.902 9.035 0.993 −0.163 0.983 24.76 0.990 17.44 0.69 0.979 −0.043 First order
F8 0.896 9.729 0.985 −0.196 0.979 26.67 0.988 18.77 0.69 0.977 −0.050 Peppas
F9 0.890 10.401 0.970 −0.249 0.980 28.55 0.989 21.48 0.655 0.9797 −0.0586 Peppas
MKT 0.928 14.969 0.979 −0.439 0.955 35.87 0.962 17.35 0.946 0.9804 −0.0946 Hix.Crow
Bilayer 0.573 11.555 0.959 −0.237 0.947 31.02 0.983 44.89 0.274 0.8991 −0.0603 Peppas
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markedly from 3 to 8 h from low to high levels of both the
polymers.
The optimized immediate layer (B6) and sustained release
layer (F6) were compressed to get bilayer tablet. The resultant
bilayer tablet (BF7) was subjected to in vitro dissolution studies.
The Figure 6 indicates the initial burst eﬀect due to immediate
release layer of VFX and then slow release of the drug is
maintained as per the Higuchi model of drug release kinetics
till 12 h. It release up to 95 ± 0.5% drug after 12 h. Drug
release proﬁle of the optimized formulations was compared with
the marketed brands of once-a-day formulations, Venlor XR
each containing 75 mg of venlafaxine hydrochloride per tablet
(Figure 6).
From the in vitro release studies of marketed formulation only
16% drug released in ﬁrst hour. Drug release was found to follow
zero order kinetics for marketed formulation. The formulation
was found to provide sustained release for a period of 24 h
with 96% drug being released in 12 h. The drug release proﬁles
from the marketed formulations are shown in Figure 6. Our BF1
batch shows 40% of drug release in ﬁrst hour and more than
80% of drug releases in 12 h. Our aim was to achieve 98–100%
release in 24 h. Hence batch BF1 was chosen for stability. There
was no change in the diﬀerent physico-chemical parameters of
the tablets at 40◦C and 70% RH conditions of temperature and
humidity.
Conclusion
A bilayer tablets of VFX containing sustained release layer
and immediate release layer were successfully formulated.
Release was found to follow zero, krossmayer–peppas, and
Hixon–crowel models. All the formulation batches tested for
physical parameters like weight variation, hardness, friability
and drug content, all were found to be within the USP
limits. The optimized formulations were found to be stable
at all the stability conditions. During stability studies, no
signiﬁcant variation (1–4%) in drug release was observed,
indicating that formulation batch BF7 was stable over the
chosen condition for 3 months. The optimized formulation
BF1 showed better drug release proﬁle as compare to marketed
formulation Venlor XR. Combination of FNM and HPMC
is an interesting polymer mixture for the preparation of
SR matrix tablet because of good bioadhesive property,
non toxicity and low cost of fenugreek and good binding
capacity.
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